NCT00790998

Study Comparing Moxidectin And Ivermectin In Subjects With Onchocerca Volvulus Infection

A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,497 (actual)
• Sponsor: Medicines Development for Global Health · Academic / Other
• Sex: All
• Age: 12 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 3 study comparing the efficacy, safety and tolerability of moxidectin and ivermectin in subjects infected with Onchocerca volvulus, which is the parasite that causes river blindness. Subjects participating in the study will be randomly assigned (by a 2 to1 ratio) to receive one orally-administered dose of either moxidectin or ivermectin.

Conditions

• Onchocerciasis

Interventions

Type	Name	Description
DRUG	Moxidectin	Single dose of moxidectin 2 mg oral tablet x 4
DRUG	Ivermectin	Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4

Timeline

• Start date: 2009-04-01
• Primary completion: 2012-02-01
• Completion: 2012-05-01
• First posted: 2008-11-14
• Last updated: 2018-01-31

Locations

4 sites across 3 countries: Democratic Republic of the Congo, Ghana, Liberia